M 161
Alternative Names: M-161Latest Information Update: 14 Mar 2023
At a glance
- Originator M6P Therapeutics
- Class Enzymes
- Mechanism of Action GALNS protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Mucopolysaccharidosis IV
Most Recent Events
- 13 Feb 2023 M 161 is available for licensing as of 13 Feb 2023. https://m6ptherapeustg.wpenginepowered.com/about-us/collaboration/
- 13 Feb 2023 Early research in Mucopolysaccharidosis IV in USA prior to February 2023 (Parenteral) (M6P Therapeutics website, February 2023)